tegafur has been researched along with Anorexia in 78 studies
Anorexia: The lack or loss of APPETITE accompanied by an aversion to food and the inability to eat. It is the defining characteristic of the disorder ANOREXIA NERVOSA.
Excerpt | Relevance | Reference |
---|---|---|
"We investigated the efficacy and safety of oral Uracil/tegafur (UFT) with leucovorin and mitomycin C (MMC) as third-line treatment for patients with extensively pretreated metastatic colorectal cancer (mCRC)." | 9.16 | Uracil-tegafur/leucovorin and mitomycin C salvage therapy in patients with advanced colorectal cancer: a phase II study. ( Chamorey, E; Dahan, L; Evesque, L; Follana, P; Francois, E; Mari, V; Michel, C; Perrier, H; Seitz, JF; Smith, D, 2012) |
"Sorafenib, a multi-kinase inhibitor with anti-angiogenic activity, was recently approved for the treatment of advanced hepatocellular carcinoma (HCC)." | 9.14 | Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. ( Chen, PJ; Cheng, AL; Ding, YH; Hsu, C; Hsu, CH; Lin, ZZ; Shao, YY; Shen, YC, 2010) |
"We performed a controlled study to compare the response to cyclophosphamide (CPA), adriamycin (ADM), and fluorouracil (5-FU) (CAF therapy) with that to uracil-tegafur (UFT) plus tamoxifen (TAM) (UFT+TAM therapy), when given as postoperative adjuvant therapy to women with breast cancer." | 9.12 | [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant set ( Inaji, H; Koyama, H; Mori, T; Nakao, K; Oka, T; Oshima, A; Ozawa, K; Saito, Y; Sakai, K; Senoo, T; Taguchi, T; Terasawa, T, 2006) |
"Combined treatment with S-1 and irinotecan is an effective, well tolerated, and convenient regimen in patients with advanced colorectal cancer." | 9.12 | Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. ( Goto, A; Hamaguchi, T; Kato, K; Muro, K; Shimada, Y; Shirao, K; Yamada, Y; Yasui, H, 2006) |
"Forty patients with bladder cancer who underwent radiotherapy with angiotensin II, a hypertensor, and two cycles of arterial infusion of anticancer chemotherapies, including cisplatin 100 mg/body, were randomly assigned to a granisetron group and a non-granisetron group for comparative study of its prophylactic effect on nausea, vomiting and anorexia." | 9.08 | [The preventive effect of granisetron on digestive tract symptoms induced by arterial infusion of anticancer and hypertensive agents in combination with radiotherapy--a study of forty patients with bladder cancer]. ( Hayashida, S; Hirasawa, T; Mitsui, H; Nasu, T; Shinohara, Y; Uchiyama, K, 1995) |
"The uracil/tegafur (UFT) plus oral Leucovorin (LV) regimen is one of the standard chemotherapy modalities for colorectal cancer, and has been reported to have fewer side effects." | 7.73 | [Efficacy of uracil/tegafur (UFT) plus oral Leucovorin (LV) therapy for colorectal cancer in elderly patients]. ( Hoki, M; Ito, T; Iwamoto, T; Iwase, K; Kanou, T; Mizuno, H; Mizushima, T; Nakamori, Y; Ozawa, H; Souma, Y, 2006) |
"A comparative study was performed to evaluate the efficacy and safety of 5'-DFUR and tegafur in recurrent breast cancer." | 7.67 | [A comparative study of 5'-DFUR and tegafur in recurrent breast cancer]. ( Abe, O; Ogawa, N; Taguchi, T; Terasawa, T; Tominaga, T; Yoshida, Y, 1985) |
"Mirtazapine is a new antidepressant called noradrenergic and specific serotonergic antidepressant(NaSSA)and blocks 5-HT3 receptors to improve nausea." | 5.38 | [Low-dose mirtazapine improved nausea and appetite loss during S-1 therapy]. ( Imai, E; Ito, T; Nishimura, D; Shibahara, H; Uematsu, N, 2012) |
"We investigated the efficacy and safety of oral Uracil/tegafur (UFT) with leucovorin and mitomycin C (MMC) as third-line treatment for patients with extensively pretreated metastatic colorectal cancer (mCRC)." | 5.16 | Uracil-tegafur/leucovorin and mitomycin C salvage therapy in patients with advanced colorectal cancer: a phase II study. ( Chamorey, E; Dahan, L; Evesque, L; Follana, P; Francois, E; Mari, V; Michel, C; Perrier, H; Seitz, JF; Smith, D, 2012) |
"Sorafenib, a multi-kinase inhibitor with anti-angiogenic activity, was recently approved for the treatment of advanced hepatocellular carcinoma (HCC)." | 5.14 | Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. ( Chen, PJ; Cheng, AL; Ding, YH; Hsu, C; Hsu, CH; Lin, ZZ; Shao, YY; Shen, YC, 2010) |
"We performed a controlled study to compare the response to cyclophosphamide (CPA), adriamycin (ADM), and fluorouracil (5-FU) (CAF therapy) with that to uracil-tegafur (UFT) plus tamoxifen (TAM) (UFT+TAM therapy), when given as postoperative adjuvant therapy to women with breast cancer." | 5.12 | [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant set ( Inaji, H; Koyama, H; Mori, T; Nakao, K; Oka, T; Oshima, A; Ozawa, K; Saito, Y; Sakai, K; Senoo, T; Taguchi, T; Terasawa, T, 2006) |
"Two phase III studies revealed an oral UFT/Leucovorin (LV) regimen, in which the drugs are taken for 28 consecutive days every 35 days, which proved to be equivalent to an infusional 5-fluorouracil/LV regimen for metastatic colorectal cancer (CRC)." | 5.12 | [Feasibility of weekday-on/weekend-off oral UFT/Leucovorin schedule as postoperative adjuvant chemotherapy for colorectal cancer]. ( Maeda, Y; Makuuchi, H; Murayama, C; Sadahiro, S; Suzuki, T, 2006) |
"Combined treatment with S-1 and irinotecan is an effective, well tolerated, and convenient regimen in patients with advanced colorectal cancer." | 5.12 | Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. ( Goto, A; Hamaguchi, T; Kato, K; Muro, K; Shimada, Y; Shirao, K; Yamada, Y; Yasui, H, 2006) |
" Major toxicities were leukopenia (38%), anorexia (27%), increased total bilirubin concentration (25%) and diarrhea (24%)." | 5.10 | [Efficacy and safety of novel oral fluoropyrimidine anticancer drug, TS-1 for advanced and recurrent gastric cancer patients]. ( Arai, K; Honma, S; Iwasaki, Y; Kimura, Y; Takahashi, K; Takahashi, T; Yamaguchi, T, 2003) |
"Forty patients with bladder cancer who underwent radiotherapy with angiotensin II, a hypertensor, and two cycles of arterial infusion of anticancer chemotherapies, including cisplatin 100 mg/body, were randomly assigned to a granisetron group and a non-granisetron group for comparative study of its prophylactic effect on nausea, vomiting and anorexia." | 5.08 | [The preventive effect of granisetron on digestive tract symptoms induced by arterial infusion of anticancer and hypertensive agents in combination with radiotherapy--a study of forty patients with bladder cancer]. ( Hayashida, S; Hirasawa, T; Mitsui, H; Nasu, T; Shinohara, Y; Uchiyama, K, 1995) |
"A combination therapy of irinotecan hydrochloride (CPT-11) with continuous intravenous infusions of (infusional) 5-fluorouracil (5-FU) and Leucovorin (LV) is often used to treat advanced colorectal cancer." | 4.83 | [The current evidence of S-1 and irinotecan hydrochloride combination chemotherapy with tri-weekly schedule]. ( Goto, A, 2006) |
"The uracil/tegafur (UFT) plus oral Leucovorin (LV) regimen is one of the standard chemotherapy modalities for colorectal cancer, and has been reported to have fewer side effects." | 3.73 | [Efficacy of uracil/tegafur (UFT) plus oral Leucovorin (LV) therapy for colorectal cancer in elderly patients]. ( Hoki, M; Ito, T; Iwamoto, T; Iwase, K; Kanou, T; Mizuno, H; Mizushima, T; Nakamori, Y; Ozawa, H; Souma, Y, 2006) |
"A comparative study was performed to evaluate the efficacy and safety of 5'-DFUR and tegafur in recurrent breast cancer." | 3.67 | [A comparative study of 5'-DFUR and tegafur in recurrent breast cancer]. ( Abe, O; Ogawa, N; Taguchi, T; Terasawa, T; Tominaga, T; Yoshida, Y, 1985) |
"A phase II evaluation of UFT, a mixture of tegafur and uracil, was performed in 13 patients with non-small cell lung cancer (eight patients with adenocarcinoma and five patients with squamous cell carcinoma)." | 3.67 | [A phase II study of UFT in non-small cell lung cancer]. ( Hojo, F; Inoue, I; Kimura, K; Nakamura, Y; Nakanishi, S; Noda, Y; Shimizu, E; Sone, S; Yagi, M; Yamasaki, K, 1986) |
"Patients with stage III gastric cancer who underwent D2 gastrectomy were enrolled." | 3.01 | Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer. ( Hirahara, N; Hyakudomi, R; Ishitobi, K; Kaji, S; Matsubara, T; Tajima, Y; Takai, K; Uchida, Y; Yamamoto, T, 2021) |
"The prognosis for locally advanced gastric cancer is poor despite advances in adjuvant chemotherapy." | 2.79 | Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial. ( Buyse, M; Fukushima, R; Hara, A; Imamura, H; Kobayashi, M; Kojima, H; Miyashita, Y; Morita, S; Nishikawa, K; Nozaki, I; Oba, K; Sakamoto, J; Takahashi, M; Takahashi, N; Takiguchi, N; Tanabe, K; Tatsumoto, N; Tsuburaya, A; Yoshida, K; Yoshino, S, 2014) |
"Patients with advanced pancreatic cancer who had received no prior chemotherapy were eligible for this study." | 2.79 | A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer. ( Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Saito, K; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Yamamoto, K; Yamamoto, N, 2014) |
"Patients with advanced or recurrent gastric cancer were randomly assigned to an experimental arm or a control arm." | 2.78 | A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancer. ( Ba, Y; Deng, T; Guo, Z; Hu, C; Huang, D; Meng, J; Wan, H; Wang, M; Xiong, J; Xu, N; Yan, Z; Yao, Y; Yu, Z; Zhang, Y; Zheng, R; Zhuang, Z, 2013) |
"Gemcitabine was administered at a dose of 1000 mg/m(2) over 30 min on days 1 and 8, and oral S-1 at a dose of 40 mg/m(2) twice daily from days 1 to 14, repeated every 3 weeks." | 2.76 | Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer. ( Boku, N; Funakoshi, A; Furuse, J; Moriyasu, F; Nakamori, S; Ohkawa, S; Okusaka, T; Sato, T; Tanaka, K; Ueno, H; Yamao, K; Yokosuka, O, 2011) |
"Patients with histological proof of prostate cancer refractory to hormonal therapies were eligible." | 2.75 | Efficacy of S-1 in patients with castration-resistant prostate cancer: a phase II study. ( Akaza, H; Fujimoto, H; Ikemoto, I; Kobayashi, M; Naito, S; Namiki, M; Tsukamoto, T; Usami, M, 2010) |
"We developed a combination chemotherapy, comprising weekly dosing of iv cisplatin (days 1 and 8) combined with a fixed dose (70 mg/m2/day) of S-1 (days 1-14) for patients with metastatic gastric cancer." | 2.72 | [S-1 combined with weekly dosing of cisplatin for metastatic gastric cancer]. ( Hyodo, I, 2006) |
"Grade 4 neutropenia was observed in one of the 59 patients (1." | 2.72 | [Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer]. ( Kawahara, M; Yumine, K, 2006) |
" We assumed that the recommended dosage of TXT was 30 mg/m(2) and that of TS-1 was 60 mg/m(2) with radiotherapy of 60 Gy." | 2.72 | [A phase I/II study of docetaxel/TS-1 with radiation for esophageal cancer patients--step 1]. ( Higashida, M; Hirabayashi, Y; Hirai, T; Hiratsuka, J; Imajyo, Y; Kawabe, Y; Matsumoto, H; Murakami, H; Tsunoda, T; Urakami, A; Yamashita, K, 2006) |
"The incidence and mortality of pancreatic cancer has increased very rapidly in Japan." | 2.72 | [Combination chemotherapy with gemcitabine and S-1 for advanced pancreatic cancer]. ( Ishihara, T; Nakamura, K; Saisho, H; Sudo, K; Yamaguchi, T, 2006) |
"Forty-eight patients with unresectable gastric cancer were enrolled for a randomized trial of FP (n = 24) vs FEP (n = 24) combination chemotherapy with respect to their effects on survival period." | 2.68 | [Combination chemotherapy with FP versus FEP in patients with advanced gastric cancer. Research group of gastric cancer chemotherapy]. ( Horiuchi, Y; Ina, K; Iwase, H; Kaneko, H; Kuroiwa, A; Kusugami, K; Morise, K; Oka, Y; Shinoda, M; Suga, S, 1995) |
"Most cases of head and neck squamous cell carcinoma (HNSCC) are in the advanced stages, resulting in a poor prognosis." | 2.43 | [Adjuvant chemotherapy with S-1 for advanced head and neck carcinoma]. ( Horiuchi, C; Ishitoya, J; Katori, H; Matsuda, H; Mikami, Y; Taguchi, T; Toth, G; Tsukuda, M; Yoshida, T, 2006) |
" Furthermore, weekly paclitaxel was found to have a better toxicity profile and to be as effective as an equivalently dosed conventional schedule of delivery every 3 weeks." | 2.43 | [S-1 combined with weekly paclitaxel in patients with advanced gastric cancer]. ( Gotoh, M; Kawabe, S; Takiuchi, H, 2006) |
"Chemotherapy for colorectal cancer is now improving rapidly due to new drugs like oxaliplatin and molecular targeting drugs." | 2.43 | [S-1 as a single agent for colorectal cancer]. ( Eguchi, T; Shirao, K, 2006) |
"The prognosis for locally advanced gastric cancer (AGC) remains unsatisfactory, even with S-1 adjuvant chemotherapy." | 1.43 | Efficacy of neoadjuvant chemotherapy with docetaxel, cisplatin and S-1 for resectable locally advanced gastric cancer. ( Aizawa, M; Matsuki, A; Migita, K; Nashimoto, A; Yabusaki, H, 2016) |
" Neutropenia, thrombocytopenia, nausea/vomiting and anorexia are the major treatment-related adverse events." | 1.38 | [A safety analysis in patients treated with oxaliplatin plus S-1 as adjuvant therapy for gastric cancer]. ( Chi, Y; Huang, J; Lü, X; Qu, T; Wang, JW; Yang, L; Zhou, Y, 2012) |
"Patients who had Japanese Gastric Cancer Association (JGCA) cStage IIIB gastric cancer were enrolled onto this study and received oral S-1 (65 mg/m(2)/day) administration and 50-Gy radiotherapy followed by radical surgery." | 1.38 | Pilot feasibility study of neoadjuvant chemoradiotherapy with S-1 in patients with locally advanced gastric cancer featuring adjacent tissue invasion or JGCA bulky N2 lymph node metastases. ( Hagiike, M; Inoue, T; Kimura, T; Okano, K; Suzuki, Y; Usuki, H; Yachida, S, 2012) |
"Mirtazapine is a new antidepressant called noradrenergic and specific serotonergic antidepressant(NaSSA)and blocks 5-HT3 receptors to improve nausea." | 1.38 | [Low-dose mirtazapine improved nausea and appetite loss during S-1 therapy]. ( Imai, E; Ito, T; Nishimura, D; Shibahara, H; Uematsu, N, 2012) |
" Thus, TS-1 and CPT-11 combination therapy has been effective for 17 months, suggesting that it is promising for long-term administration and survival to continue it perseveringly." | 1.33 | [A case of non-curatively resected gastric cancer successfully treated over 17 months with TS-1 and irinotecan combination therapy]. ( Kawamura, S; Okumura, S; Shimada, E; Sumi, Y; Tei, M; Yamagishi, D, 2006) |
"We report two metastatic pancreatic cancer patients who showed marked tumor shrinkage following administration of the oral fluorinated pyrimidine anticancer drug, S-1." | 1.33 | [Two patients effectively treated by S-1 monotherapy for metastatic pancreatic cancer]. ( Ikeda, M; Ueno, H, 2006) |
"We report a rare patient with a DPD deficiency." | 1.33 | [A case of recurrent gastric cancer with dihydropyrimidine dehydrogenase (DPD) deficiency]. ( Arai, K; Hashimoto, T; Hiruma, K; Iwasaki, Y; Matsumoto, H; Saze, Z; Takahashi, K; Yamaguchi, T; Yamashita, Y; Yasutome, M, 2006) |
"There were PR cases in hepatoma and breast cancer also." | 1.27 | [Clinical results of treatment with the UFT fine granule preparation under cooperative study. Tokyo Cancer Chemotherapy Cooperative Study Group]. ( Futatsuki, K; Kamano, T; Komita, T; Watanabe, H, 1987) |
" Total Ftorafur (FT) results using the same criteria from the UFT phase II study revealed, from a comparison of dosage and disease type, that UFT did not enhance FT side effects; rather, it markedly increases effectiveness." | 1.27 | [Report on nationwide pooled data and cohort investigation in UFT phase II study]. ( Kimura, K; Ota, K; Taguchi, T, 1987) |
"Forty cases with head and neck cancer were entered in the trial, of which 37 were perfectly evaluable." | 1.27 | [A phase II study of Futraful suppository in head and neck cancer]. ( Furuta, S; Hanada, T; Kamachi, S; Katsuta, K; Matsumura, M; Matsunaga, S; Moriyama, I; Nobori, T; Ohyama, M; Uchizono, A, 1988) |
"Thyroid cancer, nasal cancer and paranasal sinus cancer gave the best results." | 1.27 | [Chemotherapy with FT-207 suppository (Futraful Supo) in head and neck cancer--cooperative studies by six medical schools in Kanagawa Prefecture]. ( Hattori, Y; Horiuchi, M; Miyake, H; Murakami, T; Otake, H; Sawaki, S; Takahashi, H; Takeyama, I; Tamamushi, N; Yao, K, 1985) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 10 (12.82) | 18.7374 |
1990's | 11 (14.10) | 18.2507 |
2000's | 34 (43.59) | 29.6817 |
2010's | 20 (25.64) | 24.3611 |
2020's | 3 (3.85) | 2.80 |
Authors | Studies |
---|---|
Hirahara, N | 1 |
Matsubara, T | 1 |
Kaji, S | 1 |
Yamamoto, T | 2 |
Hyakudomi, R | 1 |
Takai, K | 1 |
Ishitobi, K | 1 |
Uchida, Y | 1 |
Tajima, Y | 1 |
Kobayashi, S | 2 |
Ueno, M | 1 |
Ogawa, G | 1 |
Fukutomi, A | 2 |
Ikeda, M | 3 |
Okusaka, T | 3 |
Sato, T | 3 |
Ito, Y | 1 |
Kadota, T | 1 |
Ioka, T | 1 |
Sugimori, K | 1 |
Sata, N | 1 |
Nakamori, S | 2 |
Shimizu, K | 1 |
Mizuno, N | 1 |
Ishii, H | 1 |
Furuse, J | 2 |
Okamoto, K | 1 |
Kaku, R | 1 |
Oshio, Y | 1 |
Hanaoka, J | 1 |
Li, J | 1 |
Xu, R | 1 |
Xu, J | 1 |
Denda, T | 2 |
Ikejiri, K | 1 |
Shen, L | 1 |
Toh, Y | 1 |
Shimada, K | 3 |
Kato, T | 2 |
Sakai, K | 2 |
Yamamoto, M | 1 |
Mishima, H | 1 |
Wang, J | 1 |
Baba, H | 2 |
Huang, D | 1 |
Ba, Y | 1 |
Xiong, J | 1 |
Xu, N | 1 |
Yan, Z | 1 |
Zhuang, Z | 1 |
Yu, Z | 2 |
Wan, H | 1 |
Zhang, Y | 1 |
Deng, T | 1 |
Zheng, R | 1 |
Guo, Z | 1 |
Hu, C | 1 |
Wang, M | 1 |
Yao, Y | 1 |
Meng, J | 1 |
Takeda, H | 1 |
Nishikawa, H | 1 |
Tsumura, T | 1 |
Sekikawa, A | 1 |
Maruo, T | 1 |
Okabe, Y | 1 |
Kimura, T | 2 |
Wakasa, T | 1 |
Osaki, Y | 1 |
Tsuburaya, A | 1 |
Yoshida, K | 2 |
Kobayashi, M | 2 |
Yoshino, S | 1 |
Takahashi, M | 1 |
Takiguchi, N | 1 |
Tanabe, K | 2 |
Takahashi, N | 1 |
Imamura, H | 2 |
Tatsumoto, N | 1 |
Hara, A | 1 |
Nishikawa, K | 1 |
Fukushima, R | 1 |
Nozaki, I | 1 |
Kojima, H | 1 |
Miyashita, Y | 1 |
Oba, K | 1 |
Buyse, M | 1 |
Morita, S | 3 |
Sakamoto, J | 2 |
Nakai, Y | 1 |
Isayama, H | 1 |
Saito, K | 1 |
Sasaki, T | 2 |
Takahara, N | 1 |
Hamada, T | 2 |
Mizuno, S | 1 |
Miyabayashi, K | 1 |
Yamamoto, K | 1 |
Mohri, D | 1 |
Kogure, H | 1 |
Yamamoto, N | 1 |
Hirano, K | 1 |
Ijichi, H | 1 |
Tateishi, K | 1 |
Tada, M | 1 |
Koike, K | 1 |
Migita, K | 1 |
Nashimoto, A | 1 |
Yabusaki, H | 1 |
Matsuki, A | 1 |
Aizawa, M | 1 |
Honda, G | 1 |
Kurata, M | 1 |
Okuda, Y | 1 |
Sakamoto, K | 1 |
Karasawa, K | 1 |
Chang, T | 1 |
Egawa, N | 1 |
Kamisawa, T | 1 |
Omuro, Y | 1 |
Tsuruta, K | 1 |
Koizumi, W | 1 |
Akiya, T | 1 |
Sato, A | 1 |
Sakuyama, T | 1 |
Sasaki, E | 1 |
Tomidokoro, T | 1 |
Fujimori, M | 1 |
Kikuchi, Y | 1 |
Mine, T | 1 |
Yamaguchi, K | 1 |
Kurihara, M | 3 |
Hsu, CH | 1 |
Shen, YC | 1 |
Lin, ZZ | 1 |
Chen, PJ | 1 |
Shao, YY | 1 |
Ding, YH | 1 |
Hsu, C | 1 |
Cheng, AL | 1 |
Tsunoda, A | 1 |
Nakao, K | 2 |
Watanabe, M | 2 |
Sudo, K | 2 |
Yamaguchi, T | 4 |
Ishihara, T | 2 |
Nakamura, K | 3 |
Hara, T | 1 |
Tawada, K | 1 |
Imagumbai, T | 1 |
Araki, H | 1 |
Sakai, M | 1 |
Hatano, K | 1 |
Kawakami, H | 1 |
Uno, T | 1 |
Ito, H | 1 |
Yokosuka, O | 2 |
Akaza, H | 2 |
Ikemoto, I | 1 |
Namiki, M | 1 |
Usami, M | 1 |
Fujimoto, H | 1 |
Tsukamoto, T | 1 |
Naito, S | 1 |
Tsushima, T | 1 |
Hironaka, S | 1 |
Boku, N | 2 |
Machida, N | 1 |
Yamazaki, K | 1 |
Yasui, H | 2 |
Taku, K | 1 |
Onozawa, Y | 1 |
Ueno, H | 3 |
Yamao, K | 1 |
Funakoshi, A | 1 |
Ohkawa, S | 1 |
Tanaka, K | 3 |
Moriyasu, F | 1 |
Shibahara, H | 1 |
Ito, T | 2 |
Uematsu, N | 1 |
Imai, E | 1 |
Nishimura, D | 1 |
Inoue, T | 1 |
Yachida, S | 1 |
Usuki, H | 1 |
Hagiike, M | 1 |
Okano, K | 1 |
Suzuki, Y | 1 |
Francois, E | 1 |
Smith, D | 1 |
Dahan, L | 1 |
Michel, C | 1 |
Perrier, H | 1 |
Mari, V | 1 |
Seitz, JF | 1 |
Follana, P | 1 |
Evesque, L | 1 |
Chamorey, E | 1 |
Kunisaki, C | 1 |
Ono, HA | 1 |
Hasegawa, S | 1 |
Oshima, T | 1 |
Fujii, S | 1 |
Tokuhisa, M | 1 |
Izumisawa, Y | 1 |
Takagawa, R | 1 |
Kimura, J | 1 |
Kosaka, T | 1 |
Makino, H | 1 |
Akiyama, H | 1 |
Endo, I | 1 |
Zhou, Y | 1 |
Huang, J | 1 |
Yang, L | 1 |
Chi, Y | 1 |
Qu, T | 1 |
Lü, X | 1 |
Wang, JW | 1 |
Nakata, K | 1 |
Sakata, K | 1 |
Someya, M | 1 |
Miura, K | 1 |
Hayashi, J | 1 |
Hori, M | 1 |
Takagi, M | 1 |
Himi, T | 1 |
Kondo, A | 1 |
Hareyama, M | 1 |
Fujimori, S | 1 |
Kurita, H | 1 |
Azegami, T | 1 |
Koike, T | 1 |
Ohtsuka, A | 1 |
Kobayashi, H | 1 |
Kurashina, K | 1 |
Arai, K | 2 |
Iwasaki, Y | 2 |
Kimura, Y | 2 |
Takahashi, K | 2 |
Honma, S | 2 |
Takahashi, T | 3 |
Shima, Y | 1 |
Horimi, T | 1 |
Nishioka, Y | 1 |
Okabayashi, T | 1 |
Hamada, M | 1 |
Ishikawa, T | 1 |
Shibuya, Y | 1 |
Sakurama, K | 1 |
Nishie, M | 1 |
Iwata, J | 1 |
Tsuji, A | 1 |
Saeki, T | 1 |
Takashima, S | 1 |
Sano, M | 1 |
Horikoshi, N | 2 |
Miura, S | 1 |
Shimizu, S | 1 |
Morimoto, K | 1 |
Kimura, M | 3 |
Taguchi, T | 6 |
Johira, H | 1 |
Yunoki, S | 1 |
Kawata, N | 1 |
Watanabe, N | 1 |
Hachisuka, Y | 1 |
Uomoto, M | 1 |
Hatano, H | 1 |
Sanada, E | 1 |
Watanabe, R | 1 |
Ohmori, K | 1 |
Miyata, N | 1 |
Nakashima, T | 1 |
Kuratomi, Y | 1 |
Masuda, M | 1 |
Hirakawa, N | 1 |
Shioyama, Y | 1 |
Umezaki, T | 1 |
Komune, S | 1 |
Sadahiro, S | 2 |
Mitomi, T | 1 |
Noto, T | 1 |
Kumada, K | 1 |
Hiki, Y | 1 |
Yamakawa, T | 1 |
Amano, T | 1 |
Oki, S | 1 |
Otani, Y | 1 |
Oka, H | 1 |
Takemiya, S | 1 |
Nishiyama, K | 1 |
Yamamura, T | 1 |
Tsuchiya, S | 1 |
Ogawa, N | 2 |
Takahashi, I | 3 |
Emi, Y | 1 |
Kakeji, Y | 2 |
Tokunaga, E | 1 |
Ushiro, S | 1 |
Oki, E | 2 |
Maehara, Y | 3 |
Suzuki, T | 1 |
Maeda, Y | 1 |
Makuuchi, H | 1 |
Murayama, C | 1 |
Goto, A | 2 |
Yamada, Y | 1 |
Kato, K | 1 |
Hamaguchi, T | 1 |
Muro, K | 1 |
Shimada, Y | 1 |
Shirao, K | 2 |
Iwamoto, S | 1 |
Yoshioka, K | 1 |
Mizushima, T | 1 |
Mizuno, H | 1 |
Hoki, M | 1 |
Souma, Y | 1 |
Iwamoto, T | 1 |
Ozawa, H | 1 |
Kanou, T | 1 |
Nakamori, Y | 1 |
Iwase, K | 1 |
Hashimoto, T | 1 |
Saze, Z | 1 |
Matsumoto, H | 2 |
Yasutome, M | 1 |
Hiruma, K | 1 |
Yamashita, Y | 1 |
Ohtsu, A | 1 |
Hyodo, I | 1 |
Wada, Y | 1 |
Ukon, K | 1 |
Hihara, J | 1 |
Egashira, A | 1 |
Morita, M | 1 |
Gotoh, M | 1 |
Kawabe, S | 1 |
Takiuchi, H | 3 |
Eguchi, T | 1 |
Fujii, M | 1 |
Tsukuda, M | 2 |
Ishitoya, J | 1 |
Mikami, Y | 1 |
Matsuda, H | 1 |
Katori, H | 1 |
Horiuchi, C | 1 |
Yoshida, T | 1 |
Toth, G | 1 |
Yumine, K | 1 |
Kawahara, M | 1 |
Nakazawa, M | 1 |
Wataya, H | 1 |
Ichinose, Y | 1 |
Morizane, C | 1 |
Saisho, H | 1 |
Kawamura, S | 1 |
Yamagishi, D | 1 |
Tei, M | 1 |
Sumi, Y | 1 |
Shimada, E | 1 |
Okumura, S | 1 |
Inaji, H | 1 |
Oka, T | 1 |
Ozawa, K | 1 |
Saito, Y | 1 |
Senoo, T | 1 |
Terasawa, T | 2 |
Mori, T | 1 |
Koyama, H | 1 |
Oshima, A | 1 |
Hirai, T | 1 |
Hirabayashi, Y | 1 |
Murakami, H | 1 |
Higashida, M | 1 |
Kawabe, Y | 1 |
Urakami, A | 1 |
Yamashita, K | 1 |
Hiratsuka, J | 1 |
Imajyo, Y | 1 |
Tsunoda, T | 1 |
Lee, JL | 1 |
Kang, HJ | 1 |
Kang, YK | 1 |
Ryu, MH | 1 |
Chang, HM | 1 |
Kim, TW | 1 |
Sohn, HJ | 1 |
Kim, H | 1 |
Lee, JS | 1 |
Goto, M | 1 |
Furukawa, H | 1 |
Imano, M | 1 |
Imamoto, H | 1 |
Ishida, H | 1 |
Fujitani, K | 1 |
Narahara, H | 1 |
Shimokawa, T | 1 |
Nakajo, A | 1 |
Hokita, S | 1 |
Ishigami, S | 1 |
Miyazono, F | 1 |
Etoh, T | 1 |
Hamanoue, M | 1 |
Maenohara, S | 1 |
Iwashita, T | 1 |
Komatsu, H | 1 |
Satoh, K | 1 |
Aridome, K | 1 |
Natsugoe, S | 1 |
Nakano, S | 1 |
Aikou, T | 1 |
Hayashida, S | 1 |
Hirasawa, T | 1 |
Uchiyama, K | 1 |
Mitsui, H | 1 |
Nasu, T | 1 |
Shinohara, Y | 1 |
Shinoda, M | 1 |
Morise, K | 1 |
Kusugami, K | 1 |
Iwase, H | 1 |
Ina, K | 1 |
Kaneko, H | 1 |
Horiuchi, Y | 1 |
Kuroiwa, A | 1 |
Suga, S | 1 |
Oka, Y | 1 |
Kodama, S | 1 |
Nakamura, M | 1 |
Maruhashi, T | 1 |
Tokunaga, A | 1 |
Takeuchi, Y | 1 |
Sudou, N | 1 |
Adachi, S | 1 |
Shirasaka, T | 1 |
Shimamoto, Y | 1 |
Fukushima, M | 1 |
Aiba, K | 1 |
Kanamaru, R | 1 |
Hasegawa, K | 1 |
Takeda, S | 1 |
Niitani, H | 1 |
Furue, H | 1 |
Ogawa, M | 1 |
Abe, T | 1 |
Inuyama, Y | 1 |
Kida, A | 1 |
Kohno, N | 1 |
Satake, B | 1 |
Mani, S | 1 |
Kugler, JW | 1 |
Sciortino, DF | 1 |
Garcia, JC | 1 |
Ansari, RH | 1 |
Humerickhouse, R | 1 |
Michelassi, F | 1 |
Posner, MC | 1 |
Shulman, KL | 1 |
Schilsky, RL | 1 |
List, M | 1 |
Vokes, EE | 1 |
Benner, S | 1 |
Jin, ML | 1 |
Yang, BQ | 1 |
Zhang, W | 1 |
Ren, P | 1 |
Sakata, Y | 1 |
Chiba, Y | 1 |
Fukushi, G | 1 |
Matsukawa, M | 1 |
Wada, K | 1 |
Aoyama, H | 1 |
Sawada, Y | 1 |
Fukushi, M | 1 |
Kikuchi, K | 1 |
Wakui, A | 1 |
Abe, O | 1 |
Yoshida, Y | 1 |
Tominaga, T | 2 |
Shimizu, E | 1 |
Kimura, K | 2 |
Sone, S | 1 |
Inoue, I | 1 |
Nakamura, Y | 1 |
Noda, Y | 1 |
Hojo, F | 1 |
Yagi, M | 1 |
Nakanishi, S | 1 |
Yamasaki, K | 1 |
Futatsuki, K | 1 |
Komita, T | 1 |
Kamano, T | 1 |
Watanabe, H | 1 |
Ota, K | 1 |
Niijima, T | 1 |
Aso, Y | 1 |
Kameyama, S | 1 |
Koiso, K | 1 |
Kawabe, K | 1 |
Kawamura, T | 1 |
Isurugi, K | 1 |
Yokoyama, M | 1 |
Shoji, F | 1 |
Ohyama, M | 1 |
Matsumura, M | 1 |
Katsuta, K | 1 |
Nobori, T | 1 |
Furuta, S | 1 |
Matsunaga, S | 1 |
Uchizono, A | 1 |
Hanada, T | 1 |
Moriyama, I | 1 |
Kamachi, S | 1 |
Kitamura, M | 1 |
Hayashi, K | 1 |
Kosaki, G | 1 |
Naito, K | 1 |
Hisazumi, H | 1 |
Misaki, T | 1 |
Miyazaki, K | 1 |
Kosaka, S | 1 |
Miyagi, T | 1 |
Sawaki, S | 1 |
Tamamushi, N | 1 |
Takahashi, H | 1 |
Yao, K | 1 |
Takeyama, I | 1 |
Otake, H | 1 |
Miyake, H | 1 |
Horiuchi, M | 1 |
Hattori, Y | 1 |
Murakami, T | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Phase II Study of Paclitaxel Liposome Plus S-1 as Neoadjuvant Chemotherapy for Advanced Gastric Cancer[NCT02163291] | Phase 2 | 30 participants (Anticipated) | Interventional | 2013-12-31 | Not yet recruiting | ||
A Prospective,Multicentral,Open-label,Randomized,Controlled,Phase III Clinical Trial to Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.[NCT02736552] | Phase 3 | 0 participants (Actual) | Interventional | 2016-03-31 | Withdrawn | ||
Phase III Trial of S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer[NCT01671449] | Phase 3 | 338 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
8 reviews available for tegafur and Anorexia
Article | Year |
---|---|
[Combination chemotherapy of S-1 plus biweekly docetaxel for advanced and recurrent gastric cancer].
Topics: Animals; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic | 2006 |
[S-1 combined with weekly paclitaxel in patients with advanced gastric cancer].
Topics: Administration, Oral; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Clinical Tri | 2006 |
[S-1 as a single agent for colorectal cancer].
Topics: Administration, Oral; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
[The current evidence of S-1 and irinotecan hydrochloride combination chemotherapy with tri-weekly schedule].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials | 2006 |
[Combination therapy with S-1 and CDDP for head and neck cancer].
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinom | 2006 |
[Adjuvant chemotherapy with S-1 for advanced head and neck carcinoma].
Topics: Anorexia; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Drug Ad | 2006 |
[Combination chemotherapy with S-1 and cisplatin for non-small cell lung cancer].
Topics: Administration, Oral; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, N | 2006 |
[Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
Topics: Animals; Anorexia; Antimetabolites, Antineoplastic; Diarrhea; Dogs; Drug Combinations; Female; Fluor | 1998 |
43 trials available for tegafur and Anorexia
Article | Year |
---|---|
Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer.
Topics: Adenocarcinoma; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy | 2021 |
Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; China; Col | 2017 |
A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancer.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protoc | 2013 |
Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.
Topics: Adenocarcinoma; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2014 |
A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer.
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Dose-Respon | 2014 |
A Phase I Study of S-1 and Gemcitabine with Concurrent Radiotherapy in Patients with Non-Metastatic Advanced Pancreatic Cancer.
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemor | 2015 |
Phase II study of S-1 as first-line treatment for elderly patients over 75 years of age with advanced gastric cancer: the Tokyo Cooperative Oncology Group study.
Topics: Aged; Aged, 80 and over; Anorexia; Antimetabolites, Antineoplastic; Drug Combinations; Fatigue; Fema | 2010 |
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Benzenesul | 2010 |
Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer.
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Combined Modality Therapy; | 2011 |
Efficacy of S-1 in patients with castration-resistant prostate cancer: a phase II study.
Topics: Adult; Aged; Alanine Transaminase; Androgen Antagonists; Anorexia; Antimetabolites, Antineoplastic; | 2010 |
Safety and efficacy of S-1 monotherapy in elderly patients with advanced gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anemia; Anorexia; Antime | 2010 |
Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ad | 2011 |
Uracil-tegafur/leucovorin and mitomycin C salvage therapy in patients with advanced colorectal cancer: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 2012 |
Low-dose docetaxel and cisplatin combination chemotherapy for stage II/III gastric cancer showing resistance to S-1 adjuvant chemotherapy: a phase I study.
Topics: Aged; Anorexia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 2012 |
Phase I study of oral S-1 and concurrent radiotherapy in patients with head and neck cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anorexia; Antimetabolites, Antineoplastic; Carcinoma, | 2013 |
[Efficacy and safety of novel oral fluoropyrimidine anticancer drug, TS-1 for advanced and recurrent gastric cancer patients].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Bilirubin; Drug Admini | 2003 |
[A late phase II clinical study of S-1 in patients with progressed, refractory breast cancer].
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Breast Neoplasms; Diarrhea; Drug Administrat | 2004 |
[Phase I study of concurrent radiotherapy with TS-1 and vitamin A (TAR Therapy) for head and neck cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Dru | 2005 |
[Multicenter comparative study of the recurrence-inhibitory effect of oral fluoropyrimidine drugs in patients with colorectal cancer following curative resection].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Pr | 2005 |
Phase I study of S-1 and biweekly docetaxel combination chemotherapy for advanced and recurrent gastric cancer.
Topics: Adult; Aged; Alopecia; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Area Under | 2006 |
[Feasibility of weekday-on/weekend-off oral UFT/Leucovorin schedule as postoperative adjuvant chemotherapy for colorectal cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chem | 2006 |
Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Agent | 2006 |
[S-1 combined with weekly dosing of cisplatin for metastatic gastric cancer].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplat | 2006 |
[Combination chemotherapy of S-1 and docetaxel on advanced and recurrent gastric cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administratio | 2006 |
[Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-C | 2006 |
[Preoperative chemotherapy with S-1 and low-dose cisplatin for oral squamous cell carcinoma].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy | 2006 |
[S-1 monotherapy for pancreatic cancer].
Topics: Administration, Oral; Aged; Anorexia; Antimetabolites, Antineoplastic; Drug Administration Schedule; | 2006 |
[Combination chemotherapy with gemcitabine and S-1 for advanced pancreatic cancer].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Pr | 2006 |
[A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant set
Topics: Anorexia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Ne | 2006 |
[A phase I/II study of docetaxel/TS-1 with radiation for esophageal cancer patients--step 1].
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel | 2006 |
Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer.
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diarrhea; | 2008 |
Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302).
Topics: Adenocarcinoma; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Disease-Free | 2008 |
A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer.
Topics: Adenocarcinoma; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Disease Pr | 2008 |
[The preventive effect of granisetron on digestive tract symptoms induced by arterial infusion of anticancer and hypertensive agents in combination with radiotherapy--a study of forty patients with bladder cancer].
Topics: Aged; Angiotensin II; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Chil | 1995 |
[Combination chemotherapy with FP versus FEP in patients with advanced gastric cancer. Research group of gastric cancer chemotherapy].
Topics: Adenocarcinoma; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Admi | 1995 |
[Clinical results of UFT against ovarian carcinoma].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Female; | 1994 |
UFT plus cisplatin for advanced gastric cancer.
Topics: Adolescent; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diarrh | 1997 |
[Phase I study of orally administered UFT plus l-leucovorin].
Topics: Administration, Oral; Adolescent; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protoc | 1998 |
[Early phase II study of S-1 in patients with advanced head and neck cancer. S-1 Cooperative Study Group (Head and Neck Working Group)].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Carcinoma, Squamous Ce | 1998 |
Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: a University of Chicago phase II consortium study.
Topics: Adenocarcinoma; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leuc | 1998 |
[Comparative study of UFT plus mitomycin C and UFT plus doxorubicin in adenocarcinoma. Hirosaki Cooperative Group of Cancer Chemotherapy].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Proto | 1992 |
[Cooperative research of UFT E phase II study. Cooperative Study Group of UFT E in Tohoku Area].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; | 1990 |
[Preliminary report of adjuvant chemo-endocrine therapy for breast cancer].
Topics: Adult; Anorexia; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Combined Modality Therapy | 1985 |
27 other studies available for tegafur and Anorexia
Article | Year |
---|---|
Impact of Renal Function on S-1 + Radiotherapy for Locally Advanced Pancreatic Cancer: An Integrated Analysis of Data From 2 Clinical Trials.
Topics: Aged; Anorexia; Antimetabolites, Antineoplastic; Chemoradiotherapy; Clinical Trials as Topic; Drug C | 2021 |
Impact of thoracic esophageal displacement after lobectomy on the continuity of oral adjuvant chemotherapy.
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chem | 2022 |
Prominent hypereosinophilia with disseminated intravascular coagulation as an unusual presentation of advanced gastric cancer.
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Bone Marrow Neo | 2014 |
Efficacy of neoadjuvant chemotherapy with docetaxel, cisplatin and S-1 for resectable locally advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Ch | 2016 |
[Compliance of oral UFT plus leucovorin adjuvant chemotherapy in patients who underwent curative resection for colorectal cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy | 2010 |
[Low-dose mirtazapine improved nausea and appetite loss during S-1 therapy].
Topics: Aged, 80 and over; Anorexia; Antimetabolites, Antineoplastic; Drug Combinations; Histamine H1 Antago | 2012 |
Pilot feasibility study of neoadjuvant chemoradiotherapy with S-1 in patients with locally advanced gastric cancer featuring adjacent tissue invasion or JGCA bulky N2 lymph node metastases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anorexia; Antimetabolites, Antineoplastic; Chemoradiotherap | 2012 |
[A safety analysis in patients treated with oxaliplatin plus S-1 as adjuvant therapy for gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 2012 |
[Neoadjuvant chemotherapy with nedaplatin and UFT for oral squamous cell carcinomas].
Topics: Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 2003 |
[Two resected cases of advanced gastric cancer with peritoneal dissemination after successful treatment with TS-1 plus low-dose CDDP].
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationshi | 2003 |
[Results of treatment of far advanced and recurrent stomach cancer with TS-1].
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antimetabolites, Antineoplastic; Drug Administration Sched | 2005 |
[24 hour infusion of CPT-11/oral UFT/LV].
Topics: Administration, Oral; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2006 |
[Efficacy of uracil/tegafur (UFT) plus oral Leucovorin (LV) therapy for colorectal cancer in elderly patients].
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2006 |
[A case of recurrent gastric cancer with dihydropyrimidine dehydrogenase (DPD) deficiency].
Topics: Adult; Anorexia; Antimetabolites, Antineoplastic; Bone Neoplasms; Cerebral Hemorrhage; Dihydropyrimi | 2006 |
[Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer].
Topics: Aged; Anorexia; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Dr | 2006 |
[A case of non-curatively resected gastric cancer successfully treated over 17 months with TS-1 and irinotecan combination therapy].
Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; D | 2006 |
[Two patients effectively treated by S-1 monotherapy for metastatic pancreatic cancer].
Topics: Adenocarcinoma; Aged; Anorexia; Antimetabolites, Antineoplastic; Clinical Trials, Phase II as Topic; | 2006 |
[UFT].
Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combina | 1984 |
High dose mitomycin C for treatment of advanced gastric cancer.
Topics: Adult; Aged; Anorexia; Cardia; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; | 1992 |
[A comparative study of 5'-DFUR and tegafur in recurrent breast cancer].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Agents; Breast Neoplasms; Capsules; Diar | 1985 |
[A phase II study of UFT in non-small cell lung cancer].
Topics: Adenocarcinoma; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 1986 |
[Clinical results of treatment with the UFT fine granule preparation under cooperative study. Tokyo Cancer Chemotherapy Cooperative Study Group].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Breast | 1987 |
[Report on nationwide pooled data and cohort investigation in UFT phase II study].
Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Sche | 1987 |
[Collaborative study of UFT in far-advanced renal cell carcinoma. Urological Cooperative UFT Study Group].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug A | 1988 |
[A phase II study of Futraful suppository in head and neck cancer].
Topics: Aged; Anorexia; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Drug Evaluation; Female; | 1988 |
[Clinical effect of UFT on prostatic cancer].
Topics: Adenocarcinoma; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Hum | 1985 |
[Chemotherapy with FT-207 suppository (Futraful Supo) in head and neck cancer--cooperative studies by six medical schools in Kanagawa Prefecture].
Topics: Adult; Aged; Anorexia; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Fluorouracil; | 1985 |